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DISCUSSION
Dr J. Matsumura (Chicago, Ill). What further work must be
done, or is doxycycline ready for a human trial in Marfan syndrome?
Dr Baxter. The question is how do you know if your treat-
ment is helping in a disease that may progress very slowly over
decades? It’s easy to look at a mouse that only lives several months.
Before going to a patient trial, it would be helpful to have some
sort of plasmamarker that would bemore dynamic than the change
in aortic diameter.
Dr R. Thompson (St. Louis, Mo). I have a question about the
previous use of this model to test the effects of losartan as a
potential treatment for Marfan syndrome, which is now being
applied in clinical trial. Do you know how the efficacy of treatment
with doxycycline compares with losartan in this same mouse
model, and have you tried any experiments using both of those
pharmacologic therapies?
Dr Baxter. We have not used losartan yet. And our collabo-
rators on this project, Dr Dietz and Dr Ramirez, presented their
work in Science showing that they could reverse some of the
changes in another model that they developed of Marfan syn-
drome. They have not done the survival curves as we did in this
trial, so they really do not know if it is going to prolong the lifespan
of those mice or how this would compare with doxycycline.
Dr Thompson. As a follow-up, can I ask how doxycycline
affects the secondary manifestations of Marfan syndrome in these
mice, such as skeletal myopathy and pulmonary emphysema, which
losartan has also been shown to influence?
Dr Baxter. The answer to that is we do not know. We did not
study those things. But obviously that would be important.
Dr J. Black (Baltimore, Md). I had a question regarding the
applicability of doxycycline to the group of patients at large. Since
most aortic morphogenesis happens up until around age 18, could
you enlighten me, as I thought doxycycline was associated with
staining of teeth, which might prevent it from being useful in a
human setting? A parent might not want to give their child
doxycycline within a trial if it resulted in permanent brown staining
of their teeth, versus a drug like a losartan.
Dr Baxter. I agree with you. And, I think there is a question
about what the role of this would be along with losartan. Use of an
antihypertensive medication in a patient with, for example,
Raynaud’s who does not have hypertension, is often associated
with symptoms related to hypertension. Beta blockers have been
used for years in Marfan patients. My experience is that young
patients using beta blockers have a lot of side effects such as
depression and weight gain.
You are right about the teeth staining. This is not a drug that
you would want to start a child on at an early age. But there is a
large experience with doxycycline in kids with acne. I think doxy-
cycline might be an adjunct to other medical therapies in Marfan
patients.
Dr H. Atta (Cairo, Egypt). How did you choose this dose of
doxycycline? Was it based on previous reports? And, why didn’t
you choose more than one regimen?
Dr Baxter.This sounds like a lot of doxycycline. And, we have
done extensive work with doxycycline in our model of aortic
aneurysms. It turns out that if you took doxycycline 200 mg/day
that your plasma levels would be the same as the plasma levels in
these mice. And so, we chose this dose because it really is an
equivalent dose to 200 mg/day which is a normal dose of doxycy-
cline.
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